Health Care · Biotechnology
Amgen: revenue, profit and dividends
In fiscal 2025, Amgen had revenue of $36.8B, up 5.4% a year on average since 2015, and net income of $7.71B (21.0% of revenue). Its dividend per share has gone up 12 years in a row, to $9.66. It has 29% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +10.0% vs 2024
- Ticker
- AMGN · Nasdaq
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- Thousand Oaks, California
- Founded
- 1980
- In the S&P 500 since
- January 2, 1992
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Amgen Inc · CIK 0000318154
Revenue and net income
Revenue went from $14.8B in 2007 to $36.8B in 2025.
Diluted earnings per share
Diluted EPS went from $2.74 in 2007 to $14.23 in 2025. Ten-year growth: 4.6% a year.
Dividends per share
Raised 12 years in a row, every year from 2014 to 2025. Ten-year growth: 11.8% a year.
Shares outstanding
29.2% fewer shares in 2025 than in 2015 (766M → 542M): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $8.1B in 2025, 22.0% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $36.8B | $7.71B | 21.0% | $14.23 | $9.66 | 542M | $9.96B | $1.86B | $8.1B |
| 2024 | $33.4B | $4.09B | 12.2% | $7.56 | $9.13 | 541M | $11.5B | $1.1B | $10.4B |
| 2023 | $28.2B | $6.72B | 23.8% | $12.49 | $8.64 | 538M | $8.47B | $1.11B | $7.36B |
| 2022 | $26.3B | $6.55B | 24.9% | $12.11 | $7.95 | 541M | $9.72B | $936M | $8.79B |
| 2021 | $26B | $5.89B | 22.7% | $10.28 | $7.22 | 573M | $9.26B | $880M | $8.38B |
| 2020 | $25.4B | $7.26B | 28.6% | $12.31 | $6.56 | 590M | $10.5B | $608M | $9.89B |
| 2019 | $23.4B | $7.84B | 33.6% | $12.88 | $5.95 | 609M | $9.15B | $618M | $8.53B |
| 2018 | $23.7B | $8.39B | 35.3% | $12.62 | $5.41 | 665M | $11.3B | $738M | $10.6B |
| 2017 | $22.8B | $1.98B | 8.7% | $2.69 | $4.77 | 735M | $11.2B | $664M | $10.5B |
| 2016 | $23B | $7.72B | 33.6% | $10.24 | $4.15 | 754M | $10.4B | $738M | $9.62B |
| 2015 | $21.7B | $6.94B | 32.0% | $9.06 | $3.16* | 766M | $9.73B | $594M | $9.14B |
| 2014 | $20.1B | $5.16B | 25.7% | $6.70 | $2.44* | 770M | $8.95B | $718M | $8.23B |
| 2013 | $18.7B | $5.08B | 27.2% | $6.64 | $1.88* | 765M | $6.29B | $693M | $5.6B |
| 2012 | $17.3B | $4.34B | 25.2% | $5.52 | — | 787M | $5.88B | $689M | $5.19B |
| 2011 | $15.6B | $3.68B | 23.6% | $4.04 | — | 912M | $5.12B | $567M | $4.55B |
| 2010 | $15.1B | $4.63B | 30.7% | $4.79 | — | 965M | $5.79B | $580M | $5.21B |
| 2009 | $14.6B | $4.61B | 31.5% | $4.51 | — | 1.02B | $6.34B | $530M | $5.81B |
| 2008 | $15B | $4.05B | 27.0% | $3.77 | — | 1.07B | $5.99B | $672M | $5.32B |
| 2007 | $14.8B | $3.08B | 20.8% | $2.74 | — | 1.12B | $5.4B | $1.27B | $4.13B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data. * added up from quarterly reports.
About these figures
- Dividends per share for 2013–2015 are added up from the quarterly reports.
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Biotechnology companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.